A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Nicolino Ruperto, Pierre Quartier, Nico Wulffraat, Patricia Woo, Angelo Ravelli, Richard Mouy, Brigitte Bader-Meunier, Sebastiaan J. Vastert, Emanuele Noseda, Daniele D'Ambrosio, Jean Lecot, Abhijit Chakraborty, Alberto Martini, Andrea Chioato

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. Methods In this phase II, multicenter, open-label, dosage-escalation study, children with systemic JIA who were ≤4 years of age, had fever, and were receiving ≤0.4 mg/kg/day of corticosteroids were administered a single subcutaneous dose of canakinumab, 0.5-9 mg/kg of body weight, and were redosed upon relapse. Response to treatment was assessed according to an adaptation of the American College of Rheumatology (ACR) pediatric criteria for improvement. Results A total of 23 children ages 4-19 years with active disease were enrolled. Of these, 1 patient was excluded from analysis, and 3 of the reenrolled patients were included twice in the efficacy analysis. By day 15 of the first treatment cycle, 15 of 25 patients (60%) had achieved an adapted ACR Pediatric 50 response, with 4 of them achieving inactive disease status. Response was sustained over time, with 11 of 13 patients able to maintain their response throughout the study. In 8 of the 11 responders who had been receiving steroids at baseline, the steroid dosage was decreased from a mean of 0.38 mg/kg/day to 0.13 mg/kg/day over the first 5 months, and 4 of them were able to discontinue steroids. At a dose of 4 mg/kg of canakinumab given subcutaneously every 4 weeks, the median percentage of patients predicted to relapse within 4 weeks was estimated to be 6% (95% confidence interval 1-21). Therapy was generally well tolerated and few patients experienced injection-site reactions. Conclusion Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort. Based on the findings of this trial, further studies in a larger population of children with systemic JIA are warranted.

Original languageEnglish
Pages (from-to)557-567
Number of pages11
JournalArthritis and Rheumatism
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Juvenile Arthritis
Safety
Steroids
Pediatrics
Recurrence
Rheumatology
Interleukin-1
canakinumab
Adrenal Cortex Hormones
Fever
Therapeutics
Body Weight
Confidence Intervals
Injections
Antibodies
Population

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. / Ruperto, Nicolino; Quartier, Pierre; Wulffraat, Nico; Woo, Patricia; Ravelli, Angelo; Mouy, Richard; Bader-Meunier, Brigitte; Vastert, Sebastiaan J.; Noseda, Emanuele; D'Ambrosio, Daniele; Lecot, Jean; Chakraborty, Abhijit; Martini, Alberto; Chioato, Andrea.

In: Arthritis and Rheumatism, Vol. 64, No. 2, 02.2012, p. 557-567.

Research output: Contribution to journalArticle

Ruperto, N, Quartier, P, Wulffraat, N, Woo, P, Ravelli, A, Mouy, R, Bader-Meunier, B, Vastert, SJ, Noseda, E, D'Ambrosio, D, Lecot, J, Chakraborty, A, Martini, A & Chioato, A 2012, 'A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features', Arthritis and Rheumatism, vol. 64, no. 2, pp. 557-567. https://doi.org/10.1002/art.33342
Ruperto, Nicolino ; Quartier, Pierre ; Wulffraat, Nico ; Woo, Patricia ; Ravelli, Angelo ; Mouy, Richard ; Bader-Meunier, Brigitte ; Vastert, Sebastiaan J. ; Noseda, Emanuele ; D'Ambrosio, Daniele ; Lecot, Jean ; Chakraborty, Abhijit ; Martini, Alberto ; Chioato, Andrea. / A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. In: Arthritis and Rheumatism. 2012 ; Vol. 64, No. 2. pp. 557-567.
@article{8c98ae4912874041823915f643ee9cbe,
title = "A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features",
abstract = "Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. Methods In this phase II, multicenter, open-label, dosage-escalation study, children with systemic JIA who were ≤4 years of age, had fever, and were receiving ≤0.4 mg/kg/day of corticosteroids were administered a single subcutaneous dose of canakinumab, 0.5-9 mg/kg of body weight, and were redosed upon relapse. Response to treatment was assessed according to an adaptation of the American College of Rheumatology (ACR) pediatric criteria for improvement. Results A total of 23 children ages 4-19 years with active disease were enrolled. Of these, 1 patient was excluded from analysis, and 3 of the reenrolled patients were included twice in the efficacy analysis. By day 15 of the first treatment cycle, 15 of 25 patients (60{\%}) had achieved an adapted ACR Pediatric 50 response, with 4 of them achieving inactive disease status. Response was sustained over time, with 11 of 13 patients able to maintain their response throughout the study. In 8 of the 11 responders who had been receiving steroids at baseline, the steroid dosage was decreased from a mean of 0.38 mg/kg/day to 0.13 mg/kg/day over the first 5 months, and 4 of them were able to discontinue steroids. At a dose of 4 mg/kg of canakinumab given subcutaneously every 4 weeks, the median percentage of patients predicted to relapse within 4 weeks was estimated to be 6{\%} (95{\%} confidence interval 1-21). Therapy was generally well tolerated and few patients experienced injection-site reactions. Conclusion Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort. Based on the findings of this trial, further studies in a larger population of children with systemic JIA are warranted.",
author = "Nicolino Ruperto and Pierre Quartier and Nico Wulffraat and Patricia Woo and Angelo Ravelli and Richard Mouy and Brigitte Bader-Meunier and Vastert, {Sebastiaan J.} and Emanuele Noseda and Daniele D'Ambrosio and Jean Lecot and Abhijit Chakraborty and Alberto Martini and Andrea Chioato",
year = "2012",
month = "2",
doi = "10.1002/art.33342",
language = "English",
volume = "64",
pages = "557--567",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

AU - Ruperto, Nicolino

AU - Quartier, Pierre

AU - Wulffraat, Nico

AU - Woo, Patricia

AU - Ravelli, Angelo

AU - Mouy, Richard

AU - Bader-Meunier, Brigitte

AU - Vastert, Sebastiaan J.

AU - Noseda, Emanuele

AU - D'Ambrosio, Daniele

AU - Lecot, Jean

AU - Chakraborty, Abhijit

AU - Martini, Alberto

AU - Chioato, Andrea

PY - 2012/2

Y1 - 2012/2

N2 - Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. Methods In this phase II, multicenter, open-label, dosage-escalation study, children with systemic JIA who were ≤4 years of age, had fever, and were receiving ≤0.4 mg/kg/day of corticosteroids were administered a single subcutaneous dose of canakinumab, 0.5-9 mg/kg of body weight, and were redosed upon relapse. Response to treatment was assessed according to an adaptation of the American College of Rheumatology (ACR) pediatric criteria for improvement. Results A total of 23 children ages 4-19 years with active disease were enrolled. Of these, 1 patient was excluded from analysis, and 3 of the reenrolled patients were included twice in the efficacy analysis. By day 15 of the first treatment cycle, 15 of 25 patients (60%) had achieved an adapted ACR Pediatric 50 response, with 4 of them achieving inactive disease status. Response was sustained over time, with 11 of 13 patients able to maintain their response throughout the study. In 8 of the 11 responders who had been receiving steroids at baseline, the steroid dosage was decreased from a mean of 0.38 mg/kg/day to 0.13 mg/kg/day over the first 5 months, and 4 of them were able to discontinue steroids. At a dose of 4 mg/kg of canakinumab given subcutaneously every 4 weeks, the median percentage of patients predicted to relapse within 4 weeks was estimated to be 6% (95% confidence interval 1-21). Therapy was generally well tolerated and few patients experienced injection-site reactions. Conclusion Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort. Based on the findings of this trial, further studies in a larger population of children with systemic JIA are warranted.

AB - Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. Methods In this phase II, multicenter, open-label, dosage-escalation study, children with systemic JIA who were ≤4 years of age, had fever, and were receiving ≤0.4 mg/kg/day of corticosteroids were administered a single subcutaneous dose of canakinumab, 0.5-9 mg/kg of body weight, and were redosed upon relapse. Response to treatment was assessed according to an adaptation of the American College of Rheumatology (ACR) pediatric criteria for improvement. Results A total of 23 children ages 4-19 years with active disease were enrolled. Of these, 1 patient was excluded from analysis, and 3 of the reenrolled patients were included twice in the efficacy analysis. By day 15 of the first treatment cycle, 15 of 25 patients (60%) had achieved an adapted ACR Pediatric 50 response, with 4 of them achieving inactive disease status. Response was sustained over time, with 11 of 13 patients able to maintain their response throughout the study. In 8 of the 11 responders who had been receiving steroids at baseline, the steroid dosage was decreased from a mean of 0.38 mg/kg/day to 0.13 mg/kg/day over the first 5 months, and 4 of them were able to discontinue steroids. At a dose of 4 mg/kg of canakinumab given subcutaneously every 4 weeks, the median percentage of patients predicted to relapse within 4 weeks was estimated to be 6% (95% confidence interval 1-21). Therapy was generally well tolerated and few patients experienced injection-site reactions. Conclusion Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort. Based on the findings of this trial, further studies in a larger population of children with systemic JIA are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84856370186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856370186&partnerID=8YFLogxK

U2 - 10.1002/art.33342

DO - 10.1002/art.33342

M3 - Article

VL - 64

SP - 557

EP - 567

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 2

ER -